Bacterial and fungal enzymes

Bacterial and fungal enzymes represent a diverse and critical class of therapeutic targets essential for the survival, replication, and pathogenicity of microbial organisms [1.1.2]. These enzymes facilitate a wide array of biological processes, including cell wall biosynthesis (e.g., peptidoglycan and beta-glucan synthesis), nucleic acid metabolism (e.g., DNA gyrase and RNA polymerase), and the production of essential lipids like ergosterol [1.1.1, 1.1.3, 1.3.2]. By targeting these enzymes, antimicrobial agents achieve selective toxicity, exploiting the structural and functional divergence between microbial proteins and their human counterparts to minimize host damage [1.1.3]. For example, beta-lactam antibiotics inhibit bacterial penicillin-binding proteins, while azole antifungals target the fungal enzyme lanosterol 14-alpha-demethylase [1.1.1, 1.1.3]. Despite their clinical success, the therapeutic utility of these targets is increasingly challenged by the emergence of antimicrobial resistance, driven by target site mutations, enzyme overproduction, or the evolution of drug-degrading enzymes like beta-lactamases [1.1.1, 1.3.5]. Furthermore, the lack of specificity in some broad-spectrum agents can lead to the inhibition of commensal microbial enzymes, resulting in dysbiosis and other safety concerns [1.3.5].

Other names

Microbial enzymesPathogenic enzymesProkaryotic and eukaryotic microbial enzymes

Drugs targeting these enzymes typically act as competitive or non-competitive inhibitors that disrupt essential biosynthetic or metabolic pathways, such as cell wall assembly, DNA replication, or ergosterol synthesis, leading to bacteriostatic or bactericidal effects [1.1.1, 1.1.3].